Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707 | EVP & Chief Commercial Officer | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTEGRA LIFESCIENCES HOLDINGS CORP
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.67 · Expires 2034-06-01 | Direct | 60,372 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 60,372 · Balance 60,372 F1: This award consists of stock options granted pursuant to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan") and will vest ratably in three equal annual installments on each of the first, second, and third anniversaries of the grant date, in each case subject to the Reporting Person's continued service through the applicable vesting dates. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 124,017 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Grant · Acquired 31,909 · Balance 124,017 F2: Grant of restricted stock units ("RSUs") pursuant to the Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3: All RSUs reported in this row were granted under the Plan and will vest ratably in three equal annual installments on each of the first, second, and third anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This award consists of stock options granted pursuant to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan") and will vest ratably in three equal annual installments on each of the first, second, and third anniversaries of the grant date, in each case subject to the Reporting Person's continued service through the applicable vesting dates.
F2: Grant of restricted stock units ("RSUs") pursuant to the Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F3: All RSUs reported in this row were granted under the Plan and will vest ratably in three equal annual installments on each of the first, second, and third anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2022 Filed Feb 14, 2022 21:51 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 6,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009350 · doc4.xml · nonDerivative · entry 3 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,727 F3 · shares: On February 11, 2022, the Compensation Committee certified that the Company achieved it's performance goal for fiscal year 2021 under the March 12, 2021 performance stock award at or above the threshold level based on a annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 12, 2022 at 200% of target, the first anniversary of the grant date. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:51 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 2,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009350 · doc4.xml · nonDerivative · entry 2 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,619 F2 · shares: On February 11, 2022, the Compensation Committee certified that the Company achieved it's performance goal for fiscal year 2021 under the March 13, 2020 performance stock award at or above the threshold level based on a annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2022 at 150% of target, the second anniversary of the grant date. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:51 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,458 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009350 · doc4.xml · nonDerivative · entry 1 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,195 F1 · shares: On February 11, 2022, the Compensation Committee certified that the Company achieved it's performance goal for fiscal year 2021 under the March 13, 2019 performance stock award at or above the threshold level based on a annual organic revenue growth over the prior fiscal year. Accordingly, 34% of the shares will vest on March 13, 2022 at 150% of target, the third anniversary of the grant date. Read SEC document |
| November 05, 2021 Filed Nov 8, 2021 22:05 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 3,450 | $71.59 | $246,991.71 |
DisclosureSEC source: 0001209191-21-063408 · doc4.xml · nonDerivative · entry 1 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,737 F1 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $71.58 to $71.60. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 20:33 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 4,000 | $71.22 | $284,886.00 |
DisclosureSEC source: 0001209191-21-050616 · doc4.xml · nonDerivative · entry 1 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,187 Read SEC document |
| August 01, 2021 Filed Aug 3, 2021 21:13 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 581 | $72.39 | $42,058.59 |
DisclosureSEC source: 0001209191-21-049400 · doc4.xml · nonDerivative · entry 1 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,187 Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:22 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 1,505 | $68.37 | $102,896.85 |
DisclosureSEC source: 0001209191-21-037172 · doc4.xml · nonDerivative · entry 1 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,768 Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:19 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 192 | $68.10 | $13,075.20 |
DisclosureSEC source: 0001209191-21-020779 · doc4.xml · nonDerivative · entry 4 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,273 Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:19 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 113 | $68.10 | $7,695.30 |
DisclosureSEC source: 0001209191-21-020779 · doc4.xml · nonDerivative · entry 3 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,465 Read SEC document |
| March 13, 2021 Filed Mar 16, 2021 20:19 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 113 | $68.10 | $7,695.30 |
DisclosureSEC source: 0001209191-21-020779 · doc4.xml · nonDerivative · entry 2 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,578 Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:19 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,721 | $0.00 Strike: $68.10 | $0.00 |
DisclosureSEC source: 0001209191-21-020779 · doc4.xml · derivative · entry 5 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,721 Underlying: Common Stock · 8,721 shares Expires 2029-03-12 F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/12/2021. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:19 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 2,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020779 · doc4.xml · nonDerivative · entry 1 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,691 Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:19 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 435 | $69.26 | $30,128.10 |
DisclosureSEC source: 0001209191-21-016852 · doc4.xml · nonDerivative · entry 2 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,798 Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:19 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 2,205 | $69.00 | $152,145.00 |
DisclosureSEC source: 0001209191-21-016852 · doc4.xml · nonDerivative · entry 1 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,233 Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:12 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | SaleCommon Stock | 2,500 | $55.55 | $138,871.00 |
DisclosureSEC source: 0001209191-20-057619 · doc4.xml · nonDerivative · entry 1 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,438 F1 · price: The price shown above represents the weighted average price of the shares sold. The range of the sale prices was $55.51 to $55.56. Read SEC document |
| November 01, 2020 Filed Nov 3, 2020 21:13 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 1,713 | $44.10 | $75,543.30 |
DisclosureSEC source: 0001209191-20-056592 · doc4.xml · nonDerivative · entry 1 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,938 Read SEC document |
| August 01, 2020 Filed Aug 4, 2020 20:11 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 317 | $47.75 | $15,136.75 |
DisclosureSEC source: 0001209191-20-044667 · doc4.xml · nonDerivative · entry 1 McBreen Michael J. · CIK 0001814943 · EVP & President, CSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,651 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.